摘要:
Objective To investigate the efficacy of Egb761 on vacuous chewing movements (VCMs) of haloperidol-induced tardive dyskinesia (TD) rats and serum levels of brain-derived neurotrophic factor (BDNF) and total antioxidant capacity (TAC), and to explore the possible mechanism of treatment. Methods Thirty-two male Sprague-Dawley (SD) rats were randomly divided into the normal saline (NS), TD, Egb761, vitamin E (VitE) group (n=8), processed with NS, haloperidol + NS, haloperidol + Egb761, haloperidol + VitE with 8 rats in each group, the test duration was 10 weeks. VCM was evaluated at each weekend. Venous blood was collected at the end of 10th week, and the serum levels of BDNF and TAC were assayed. Results (1)VCM score of TD, Egb761, VitE group increased gradually after two weeks and reached the peak at the 5th weekend, and they were significantly higher compared with that of NS group(F=8.96,P0.05);(2)At the 10th weekend, serum BDNF((6.9±1.0) ng/L), TAC((11.9±3.2) mU/L) levels of TD group were significantly lower than that of the NS ((8.6±2.5) ng/L, (18.2± 5.5) mU/L),Egb761((8.9 ± 1.5) ng/L, (19.4 ± 4.4) mU/L) and VitE group ((8.7 ± 2) ng/L, (18.6 ± 5.9) mU/L). Serum BDNF and TAC levels of the two groups were higher than that of TD group(F=4.21,F=6.67,P0.05);(3)BDNF serum concentrations were related to the TAC levels (r=0.689, P0.05);(2)BDNF和TAC比较:第10周末,TD组血清BDNF[(6.9±1.0) ng/L]、TAC[(11.9±3.2) mU/L]水平显著低于生理盐水组[(8.6±2.5) ng/L、(18.2±5.5) mU/L]、Egb761组[(8.9±1.5) ng/L、(19.4±4.4) mU/L]和VitE组[(8.7±2.0) ng/L、(18.6±5.9) mU/L],Egb761与VitE治疗后BDNF和TAC水平高于TD组(F=4.21,F=6.67,P0.05);(3)生理盐水组大鼠血清BDNF与TAC水平显著相关(r=0.689,P<0.05),另外3组未发现两者存在显著相关.结论 Egb761与VitE均可显著缓解TD模型大鼠空嚼运动症状,神经营养因子降低和自由基代谢异常可能在TD发生过程中作用关键.